Humira is a brand-name drug prescribed to treat rheumatoid arthritis, psoriatic arthritis, and more. It can remain unrefrigerated for up to 14 days, as long as the temperature doesn’t go above 77°F ...

The approval of the interchangeable designation was supported by data from a randomized, double-blind phase 4 trial (ClinicalTrials.gov Identifier: NCT05510063) that assessed the pharmacokinetics, ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

Similar PK, efficacy, safety, and immunogenicity data were observed between the adalimumab-aaty and Humira switching group vs the Humira maintenance group. The Food and Drug Administration (FDA) has ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...

Abstract: Fault injection has been a well-researched area in the dependable and reliable systems community. Nevertheless, a simple framework for fault injection that combines both software and ...

AbbVie delivered Y/Y growth in the second quarter despite Humira’s decline, with Skyrizi and Rinvoq as key growth drivers, achieving 45% and 56% Y/Y growth, respectively. I expect Skyrizi to become a ...

AbbVie did not immediately respond to a request for comment, but has previously said it expects to retain a lower share of the Humira market next year. Pharmacy benefit managers, which act as ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...